Evidence map›Paper›PMID 33191178›Full record

ArticleInternational immunopharmacology2021

Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2.

Shuangshi Wei, Shengbao Duan, Xiaomei Liu, Hongmei Wang, Shaohua Ding, Yezhou Chen, Jinsong Xie, Jingjing Tian, Nong Yu, Pingju Ge and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Avian Antibodies as Potential Therapeutic Tools.Antibodies (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Shuangshi WeiCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
Shengbao DuanCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China; University of Chinese Academy of Sciences, Beijing, China.
Xiaomei LiuCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
Hongmei WangCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
Shaohua DingCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
Yezhou ChenCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
Jinsong XieCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
Jingjing TianCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.
Nong YuDepartment of Laboratory Medicine, The People's Hospital of Suzhou New District, Suzhou, China.
Pingju GeAcrobiosystems Inc, Beijing, China.
Xinglin ZhangAcrobiosystems Inc, Beijing, China.
Xiaohong ChenAcrobiosystems Inc, Beijing, China.
Yong LiCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: szliyong@sibet.ac.cn.
Qinglin MengCAS Key Lab of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China. Electronic address: weiss@sibet.ac.cn.
Suzhou Institute of Biomedical Engineering and Technology · CNThe Fifth People’s Hospital of Suzhou · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19.

Indexed as

Angiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingChickensCOVID-19Egg YolkHumansImmunoglobulinsMutationPandemicsProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingIgYImmunoglobulinsSpike Glycoprotein, Coronavirusspike glycoprotein, SARS-CoVChicken Egg Yolk AntibodiesIgYNeutralizing agentSARS-CoV-2Spike protein variants

Identifiers

PMID33191178
PMCPMC7608017
OpenAlexW3095362375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.